What is Lifesci Capital's Forecast for CNTA Q3 Earnings?

Key Points

• Lifesci Capital forecasts Centessa Pharmaceuticals (NASDAQ: CNTA) will report Q3 2025 earnings of ($0.38) per share, maintaining a "Strong-Buy" rating for the stock.
• Other analysts have set varying ratings and price targets for Centessa, with Oppenheimer rating it "outperform" with a price objective of $40.00 and Chardan Capital setting a $30.00 target.
• Insider trading activity showed General Counsel Iqbal J. Hussain sold 6,000 shares for $103,380, indicating a decrease in insider ownership of Centessa Pharmaceuticals.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) - Investment analysts at Lifesci Capital issued their Q3 2025 earnings estimates for shares of Centessa Pharmaceuticals in a research report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($0.38) for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.

Several other analysts have also issued reports on CNTA. Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective on the stock. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target on the stock. Chardan Capital reissued a "buy" rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price target on the stock. Finally, Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $31.45.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA traded up $1.89 on Friday, hitting $22.74. The company's stock had a trading volume of 2,293,099 shares, compared to its average volume of 1,012,333. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The stock has a fifty day moving average of $16.24 and a two-hundred day moving average of $14.49. The firm has a market capitalization of $3.04 billion, a P/E ratio of -12.80 and a beta of 1.47. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $22.94.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03).

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Mario Alberto Accardi sold 15,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the transaction, the insider owned 216,485 shares in the company, valued at approximately $3,030,790. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $12.63, for a total value of $694,650.00. Following the sale, the chief executive officer directly owned 221,017 shares in the company, valued at $2,791,444.71. This represents a 19.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock worth $2,472,814 in the last ninety days. 7.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd grew its position in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after buying an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Centessa Pharmaceuticals during the first quarter worth approximately $47,000. Barclays PLC grew its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Centessa Pharmaceuticals during the first quarter worth approximately $147,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.